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Abstract Fumonisins are carcinogenic mycotoxins that are
frequently found as natural contaminants in maize from
warm climate regions around the world. The aminotrans-
ferase FumI is encoded as part of a gene cluster of
Sphingopyxis sp. MTA144, which enables this bacterial
strain to degrade fumonisin B1 and related fumonisins.
FumI catalyzes the deamination of the first intermediate of
the catabolic pathway, hydrolyzed fumonisin B1. We used a
preparation of purified, His-tagged FumI, produced recom-
binantly in Escherichia coli in soluble form, for enzyme
characterization. The structure of the reaction product was
studied by NMR and identified as 2-keto hydrolyzed
fumonisin B1. Pyruvate was found to be the preferred
co-substrate and amino group receptor (KM=490 μM at
10 μM hydrolyzed fumonisin B1) of FumI, but other α-keto
acids were also accepted as co-substrates. Addition of the
co-enzyme pyridoxal phosphate to the enzyme prepara-
tion enhanced activity, and saturation was already
reached at the lowest tested concentration of 10 μM.
The enzyme showed activity in the range of pH 6 to 10
with an optimum at pH 8.5, and in the range of 6°C to
50°C with an optimum at 35°C. The aminotransferase
worked best at low salt concentration. FumI activity
could be recovered after preincubation at pH 4.0 or
higher, but not lower. The aminotransferase was dena-
tured after preincubation at 60°C for 1 h, and the residual
activity was also reduced after preincubation at lower
temperatures. At optimum conditions, the kinetic param-
eters KM=1.1 μM and kcat=104/min were determined with
5 mM pyruvate as co-substrate. Based on the enzyme
characteristics, a technological application of FumI, in
combination with the fumonisin carboxylesterase FumD
for hydrolysis of fumonisins, for deamination and detox-
ification of hydrolyzed fumonisins seems possible, if the
enzyme properties are considered.
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Introduction
Fumonisins are a group of structurally related mycotoxins
produced by several species of Fusarium (Rheeder et al.
2002) as well as by Alternaria alternata (Chen et al. 1992),
Aspergillus niger (Frisvad et al. 2007), and Tolypocladium
D. Hartinger :G. Schatzmayr :W.-D. Moll (*)
BIOMIN Research Center,




Christian Doppler Laboratory for Mycotoxin Metabolism,
Center for Analytical Chemistry, Department
of Agrobiotechnology IFA-Tulln, University of Natural Resources
and Life Sciences, Vienna,
Konrad Lorenz Strasse 20,
3430 Tulln, Austria
C. Hametner





Food Biotechnology Laboratory, Department of Food Sciences




Appl Microbiol Biotechnol (2011) 91:757–768
DOI 10.1007/s00253-011-3248-9
species (Mogensen et al. 2011). Fusarium verticillioides
may be considered the most important fumonisin pro-
ducer from the aspect of food and feed safety, as it is an
important pathogen of maize in warm climate regions
around the world. The fumonisins produced by this
fungus were also the first to be isolated (Gelderblom et
al. 1988; Bezuidenhout et al. 1988) and thoroughly
studied (Marasas 2001). Fumonisin B1 (FB1), the most
prevalent fumonisin of F. verticillioides, can cause equine
leukoencephalomalacia (Marasas et al. 1988; Kellerman et
al. 1990), porcine pulmonary edema (Harrison et al. 1990;
Haschek et al. 2001), liver cancer in rats (Gelderblom et
al. 1991), neural tube disorder in mice (Sadler et al. 2002;
Gelineau-van Waes et al. 2005), alteration of the immune
response in pigs (Taranu et al. 2005), and shows several
other toxic effects in laboratory and domestic animals
(Voss et al. 2007). Exposure to fumonisins is also
associated with cancer and neural tube disorder in humans
(Wild and Gong 2010). At the molecular level, fumonisins
interfere with sphingolipid metabolism by inhibiting the
enzyme ceramide synthase (Wang et al. 1991). The
resulting imbalance of sphingolipids, which also have
signaling functions as cellular messenger molecules, is
responsible for toxic and carcinogenic effects of fumoni-
sins (Merrill et al. 2001; Riley et al. 2001). However, other
mechanisms of fumonisin toxicity and carcinogenicity
were also proposed, including activation of mitogen-
activated protein kinase (Wattenberg et al. 1996), lipid
peroxidation (Abel and Gelderblom 1998), and alteration
of the biosynthesis of other lipids in addition to the
sphingolipids (Gelderblom et al. 2001).
The known fumonisin biodegradation pathways in black
yeast strains (Blackwell et al. 1999) and bacteria (Duvick et
al. 2003; Heinl et al. 2010) all start with the hydrolytic
release of the two tricarballylic acid side chains, catalyzed
by a fumonisin carboxylesterase. The second step is
deamination of hydrolyzed fumonisin B1 (HFB1), either
by an amine oxidase in black yeast strains (Blackwell et al.
1999) or an aminotransferase in bacterial strains (Heinl et
al. 2010, 2011) (Fig. 1). Enzymatic detoxification of
fumonisins may be a suitable approach to increase feed
and food safety (Karlovsky 1999). However, it is unclear
whether toxicity is sufficiently reduced by enzymatic
cleavage of the two tricarballylic acid side chains. Hydro-
lyzed fumonisins were reported not to have cancer-
initiating potency (Gelderblom et al. 1993), to be less
hepatotoxic (Howard et al. 2002), less disruptive of
sphingolipid metabolism, and not inducing neural tube
disorder (Voss et al. 2009) in vivo. Hydrolysis of
fumonisins by nixtamalization was reported to reduce, but
not eliminate, toxicity (Hendrich et al. 1993; Voss et al.
1996). The in vitro effects of hydrolyzed fumonisins were
reported to range from less (Flynn et al. 1997; Norred et al.
1997; Schmelz et al. 1998; van der Westhuizen et al. 1998;
Seefelder et al. 2003) to more toxic than those of the intact
fumonisins (Gelderblom et al. 1993). The 2-amino group of
hydrolyzed fumonisins plays a key role for toxicity, since it
can be acylated both in vitro (Humpf et al. 1998) and in
vivo (Seiferlein et al. 2007), and the N-acyl-metabolites are
even more cytotoxic than FB1 (Humpf et al. 1998). In
summary, deamination in addition to removal of the side
chains may be necessary for complete fumonisin detoxifi-
cation. Since the bacterial aminotransferases, contrary to the
black yeast amine oxidases, do not require molecular
oxygen for activity, they may be more suitable for
applications in anaerobic environments, for instance as
feed or food enzymes for detoxification directly in the
intestinal tract of animals or humans. Another possible
application would be in ethanol fermentation of maize
mash, where fumonisins normally accumulate in the
distillers dried grains and solubles, which are subsequently
used as animal feed.
We have previously cloned the fumI gene of Sphingo-
pyxis sp. MTA144, which catalyzes deamination of HFB1
(Heinl et al. 2010), expressed the gene in E. coli and
purified the enzyme (Hartinger et al. 2010). Here, we report
the characterization of the enzyme together with its kinetic
parameters as a starting point for evaluation of the




13C-FB1 were obtained from Biopure Referenz-
substanzen GmbH (Tulln, Austria). HFB1 was prepared by
complete hydrolysis of FB1 with purified recombinant
carboxylesterase FumD (Heinl et al. 2010). All other
chemicals were purchased from Sigma (St. Louis, MO,
USA) or Sigma–Aldrich (Steinheim, Germany). Water was
purified by reverse osmosis in an arium® RO 61316 system
(Sartorius Stedim Biotech GmbH, Göttingen, Germany).
Recombinant enzyme production and purification
Construction of the expression vector pET-30a-AT144HIS,
gene expression in E. coli ArcticExpress(DE3), and purifica-
tion of the 6xHis-tagged recombinant aminotransferase FumI
by immobilized nickel affinity chromatography were previ-
ously described (Hartinger et al. 2010). The recombinant
enzyme FumI-HIS comprises the FumI sequence (GenBank
ACS27061) with a C-terminal extension of ASSVD
KLAAALEHHHHHH. The calculated molecular mass is
48,271.5 Da. Preparations of FumI-HIS were stored at −20°C
after addition of glycerol to 25%.
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Enzyme activity assays
Possible co-substrates of the aminotransferase were tested
in a reaction system containing 94 ng/ml FumI-HIS in
20 mM Tris–HCl pH 7.4, 50 mM NaCl, 2 mM CaCl2,
20 μM pyridoxal phosphate (PLP), and 0.1 mg/ml bovine
serum albumin (BSA). HFB1 as the substrate was employed
at a concentration of 15 μM, and no co-substrate or 15 μM
or 3 mM of the α-keto acids pyruvate, α-ketobutyrate, α-
ketoglutarate, glyoxylate, or oxaloacetate, respectively,
were added. Samples of 200 μl were taken immediately
after addition of the enzyme to the reaction mixture (t=0 h),
as well as after 0.5, 1, and 3 h of incubation in a water bath
at 25°C. For correlation of enzyme activity with pyruvate
and oxaloacetate concentration, the assay was performed as
above except with 10 μM HFB1, and co-substrate concen-
trations were varied from 0.01 to 100 mM. Aminotransfer-
ase activity was determined by calculating the slope of the
initial, linear reaction rates in Δ μmol HFB1 per liter per
minute. Oxaloacetate was dissolved directly before use to
avoid decarboxylation. To test the need for addition of PLP,
the assay was performed as above with 15 μM HFB1 and
PLP concentrations ranging from 0 to 400 μM. The effect
of salt on enzyme activity was tested by using 20 mM Tris–
HCl pH 8.0 buffers with 1,000 mM, 100 mM, 10 mM
NaCl, or without added NaCl, Teorell–Stenhagen buffer
Fig. 1 Initial steps of
fumonisin B1-degradation path-
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pH 8.0 (Teorell and Stenhagen 1938), or 100 mM potas-
sium phosphate buffer, all with 20 μM PLP, 0.1 mg/ml
BSA, 3 mM pyruvate, and 15 μM HFB1.
The optimum pH for enzyme activity was determined by
setting Teorell–Stenhagen buffer to pH values ranging from
pH 1.8 to 11.5 at 22°C (Teorell and Stenhagen 1938). The
assay was performed using 67 ng/ml FumI-HIS, 10 μM
HFB1, 20 μM PLP, 0.1 mg/ml BSA, and 5 mM pyruvate at
25°C. Samples were taken before addition of enzyme and
after 15, 30, 45, 60, 120, and 240 min. Enzyme activities
were calculated from early time points, where reaction rates
were linear, and are expressed as μM 2-keto-HFB1 formed
per minute. The optimum temperature for enzyme activity
was determined by using the same conditions as for the pH
dependence, with the buffer set to pH 8.0 at 22°C, and
incubation temperatures in water baths ranging from 6°C to
50°C. Reaction mixtures were temperature-equilibrated for
30 min before addition of enzyme.
To determine pH stability of FumI-HIS, the Teorell–
Stenhagen buffer was set to pH values between pH 1.1 and
10.7, and 14 μg/ml of enzyme was incubated in these
buffers at 35°C for 1 h. The residual enzyme activity was
determined in the same buffer at pH 7.8 after dilution of
FumI-HIS to 50 ng/ml, using 15 μM HFB1, 20 μM PLP,
0.1 mg/ml BSA, and 5 mM pyruvate. Samples were taken,
and reaction rates were determined as for the correlation of
activity with pH and temperature. The thermal stability of
FumI-HIS was determined by incubating 14 μg/ml of
enzyme in Teorell–Stenhagen buffer, set to pH 8.0 at 22°C,
for 1 h in water baths at temperatures ranging from 7°C to
60°C. Residual enzyme activity was measured at 35°C after
dilution in the same buffer with final concentrations of
FumI-HIS, HFB1, PLP, BSA, and pyruvate as described for
pH stability. Samples were taken, and reaction rates were
calculated as for the determination of optimum pH and
temperature.
Enzyme kinetics were determined by incubating
10 ng/ml FumI-HIS at 35°C in 20 mM Tris–HCl
pH 8.0, 20 μM PLP, 0.1 mg/ml BSA, and 5 mM
pyruvate, while the concentration of HFB1 was varied
from 0.1 to 100 μM. Samples were taken, and reaction
rates were determined as above.
Liquid chromatography–mass spectrometry
Samples taken from enzyme assays were inactivated at 99°C
for 10 min and stored frozen. After thawing, mixing, and
centrifugation, aliquots of samples containing nominally
0.2 nmol HFB1, but no more than 100 μl, were dried at
50°C under a stream of nitrogen and dissolved in 200 μl
solvent with 13C-FB1 as internal standard. Thus, the final
nominal HFB1 concentration for analysis was 1 μM, or less
if the original concentration was less than 2 μM. All samples
were analyzed using the previously described instrumental
setup and method (Heinl et al. 2010), to which 2-keto-HFB1
has been integrated (Hartinger et al. 2010).
Preparative isolation of 2-keto-HFB1 and structure
determination by NMR
FumI-HIS was produced in E. coli ArcticExpress (DE3) as
previously described (Hartinger et al. 2010). Biomass was
resuspended in 1/100 of the culture volume, homogenized
in a French Press, and 1.2 ml of the clarified lysate was
added to 4.05 mg HFB1 in 25 ml buffer (20 mM Tris–HCl
pH 8.0, 6.6 mM pyruvate, 30 μM PLP, and 0.1 mg/ml
BSA). After incubation at 30°C, complete deamination of
HFB1 was confirmed by liquid chromatography–mass
spectrometry (LC–MS). The reaction mixture was centri-
fuged, lyophilized, and dissolved in 6 ml of 40%
acetonitrile in water (v/v). After centrifugation, 600-μl
portions were separated on a preparative Agilent 1100
HPLC system (Agilent, Waldbronn, Germany) consisting of
a G1361A pump, a G2260A autosampler, an adjustable
flow splitter (Analytical Scientific Instruments, CA, USA),
an evaporative light-scattering detector (SEDEX LT-ELSD
Model 85, Sedere, Alfortville, France), a G1365B multi-
wavelength detector, and a G1364B fraction collector. A
Gemini-NX C18 column (150×21.2 mm, 5-μm particle size,
110-Å pore size; Phenomenex, Aschaffenburg, Germany)
protected by a Gemini C18 pre-column (15×21.2 mm) was
operated at a flow rate of 16 ml/min using gradient elution.
Mobile phase A, consisting of acetonitrile/H2O (10:90, v/v),
was degassed by membrane filtration. Acetonitrile was used
as mobile phase B. The gradient was as follows: 0–0.2 min:
0% B, 0.2–5 min: linear increase to 95% B, 5–6.4 min:
isocratic elution at 95% B, 6.4–6.5 min: linear decrease
to 0% B, 6.5–9.5 min: re-equilibration at 0% B. The
column effluent was split 1:70, one part moving into the
evaporative light-scattering detector and the main part
passing through the multivariate wavelength detector to
the fraction collector. The 2-keto-HFB1 eluted between
4.85 and 5.7 min and fractions were collected in that time
window. The combined fractions were evaporated to
dryness on a rotary evaporator, dissolved in 7 ml of ethyl
acetate, and transferred into an 8-ml screw cap vial; the
ethyl acetate solution was evaporated to dryness under a
stream of nitrogen at 50°C. The 2-keto-HFB1, a viscous,
clear, and colorless oily substance, was stored at 4°C until
NMR analysis.
1H- and 13C-NMR spectra were obtained from CD3CN
solutions using an Avance DRX-400 FT-NMR spectrometer
(Bruker BioSpin, Rheinstetten, Germany), operating at
400.13 MHz for 1H and 100.62 MHz for 13C, at 295 K
using a 5-mm inverse broadband Z-gradient probe head.
Data were recorded and evaluated using TOPSPIN 1.3
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software (Bruker Biospin). All pulse programs were taken
from the Bruker software library. Chemical shifts were
established on the basis of residual solvent resonances.
Results
Biochemical characterization of FumI-HIS
Clarified cell lysates of E. coli overexpressing the fumI
gene were previously used to obtain preliminary informa-
tion, namely that HFB1 is a substrate and that an α-keto
acid such as pyruvate is required as co-substrate for the
activity of the aminotransferase FumI (Heinl et al. 2010).
The detailed biochemical characterization reported here was
made using FumI-HIS, which was prepared and purified to
electrophoretic homogeneity as described before (Hartinger et
al. 2010). This enzyme preparation was found to be stable
for several months when stored in 25% glycerol at −20°C.
Clarified cell lysates of E. coli ArcticExpress (DE3)
producing FumI and FumI-HIS from the same expression
vector pET-30a under identical conditions showed a very
similar HFB1 deamination activity, indicating that the His-
tag does not affect the enzymatic activity.
Theα-keto acids pyruvate, α-ketobutyrate, α-ketoglutarate,
glyoxylate, and oxaloacetate were tested as potential
co-substrates for aminotransferase FumI (Fig. 2). No deami-
nation of HFB1 was detectable when no co-substrate was
added or in the presence of α-ketoglutarate, while pyruvate,
oxaloacetate, glyoxylate, and α-ketobutyrate, when included
at 3 mM concentration, supported the reaction, with HFB1
deamination efficiency decreasing in this order. When tested
with 10 μM HFB1, the enzyme showed maximal activity at
10 mM pyruvate, and the KM for pyruvate was 490 μM.
Deamination activity was significantly reduced when the
concentration of the co-substrate pyruvate was in the same
range as that of HFB1, and substrate inhibition was observed
for pyruvate concentrations in the range of 50–100 mM
(Fig. 3). With oxaloacetate as co-substrate, reaction rates were
lower, and the KM for oxaloacetate was 4,150 μM (Fig. 3).
Addition of PLP enhanced the aminotransferase activity of
FumI-HIS, and saturation was reached already at the lowest
concentration tested (10 μM PLP) since a further increase in
PLP concentration to 20, 40, 60, 80, 100, 120, 140, 160, 180,
200, 300, and 400 μM in the assay mixture did not result in a
further increase in the reaction rate. Without added PLP,
FumI-HIS showed about 23% of the maximum activity.
Addition of NaCl to the 20 mM Tris–HCl (pH 8.0)
reaction buffer reduced the HFB1 deamination rate (Fig. 4).
When using 100 mM potassium phosphate or Teorell–
Stenhagen buffer, enzyme activity was also lower than in
20-mM Tris–HCl buffer of the same pH. Nevertheless,
Teorell–Stenhagen buffer was used to determine the
optimum pH for enzyme activity, since this buffer can be
adjusted to any pH between 2.0 and 12.0 (Teorell and
Stenhagen 1938). Aminotransferase FumI-HIS was active
in the range of pH 6.5 to 9.7 and showed a rather sharp
optimum at pH 8.0 and 8.5 (Fig. 5a). The enzyme was
active over a broad temperature range of 6°C to 45°C with
an optimum for the 30 min assay at 35°C (Fig. 5b).
Significant and rapid thermal inactivation was observed at
50°C, where traces of 2-keto-HFB1 were formed only at the
Fig. 2 Comparison of HFB1 deamination activity of FumI-HIS with
five different α-keto acids as co-substrate. The reactions were
incubated in 20 mM Tris–HCl buffer (pH 7.4) at 25°C with 94 ng/ml
FumI and 3 mM α-keto acid
Fig. 3 Correlation between pyruvate concentration or oxaloacetate
concentration and HFB1 deamination activity. The reactions were
incubated with 94 ng/ml FumI-HIS and 10 μM HFB1 in 20 mM Tris–
HCl (pH 7.4) with 0.1 mg/ml BSA, 20 μM PLP, and the indicated
concentration of pyruvate or oxaloacetate at 25°C. Samples were
taken and analyzed, and reaction rates were calculated as described in
Materials and Methods. The reaction mixtures without co-substrates
(negative controls), which are not shown in the semi-logarithmic plot,
gave HFB1 deamination rates of zero
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beginning of the incubation period (data not shown).
Chromatograms of samples from the HFB1 deamination
reaction of this experiment at 35°C are shown in Fig. 6.
Furthermore, FumI-HIS was incubated with intact FB1
instead of hydrolyzed FB1 under identical conditions, but
FB1 was not deaminated. Reaction with a hydrolyzed total
fumonisin extract from F. verticillioides culture material
performed under the same conditions showed that, in
addition to HFB1, HFB2, and HFB3 were substrates of
FumI-HIS as well. When FumI-HIS was preincubated at an
acidic pH and 35°C for 1 h before HFB1 deamination was
measured, the activity was reduced after incubation at
pH 6.5 or less, and completely abolished after incubation at
pH below 4.0 (Fig. 7a). Incubation at pH 8.0 for 1 h at
various temperatures resulted in a steady decrease of FumI
activity with increasing temperature, and the enzyme was
completely inactivated after incubation at 60°C. Even after
incubation at 7°C, a 15% loss of enzyme activity compared
to non-preincubated FumI was determined (Fig. 7b).
The apparent steady-state kinetic parameters of FumI-
HIS catalyzed HFB1 deamination were determined for a
saturating co-substrate concentration of 5 mM pyruvate in
20 mM Tris–HCl buffer (pH 8.0) at 35°C, and the
Michaelis–Menten plot is shown in Fig. 8. The apparent
Vmax value of 0.022 μM/min was reached at 5 μM HFB1
when 10 ng/ml of FumI-HIS was present in the reaction
mixture. A further increase in substrate (HFB1) concentra-
tion resulted in a significant reduction of the reaction rate,
indicating substrate inhibition. The kcat value was calculated
to be 104 min−1 using the theoretical molecular mass of
FumI-HIS, and the Michaelis constant KM for HFB1 was
determined to be 1.1 μM. The specific HFB1 deamination
activity was 2.2 μmol/min/mg.
Structure determination of the reaction product by NMR
From the 1D 1H- to 13C-APT-NMR spectra, it was obvious
that the sample did not contain a single species, but three
different forms. In order to analyze the molecular structures
of these compounds, 1H1H COSY, 1H13C HSQC, and 1H13C
HMBC spectra were recorded. Using these two-dimensional
methods, all of the structures could be elucidated unambig-
uously, and complete assignments of 1H and 13C signals
were established (Table 1). Thus, the structures were
Fig. 4 Effect of different buffers and salt concentrations on the
HFB1-deamination rate of aminotransferase FumI-HIS. Negative
control: 20 mM Tris–HCl (pH 8.0) with buffer instead of enzyme
Fig. 5 Determination of optimum pH (a) and temperature (b) for
FumI-HIS activity. The reactions were incubated with 67 ng/ml FumI-
HIS and 10 μM HFB1 in Teorell–Stenhagen buffer, with supplements
as described in Materials and Methods, set to the indicated pH values
(a) or to pH 8.0 (b), at 25°C (a) or the indicated temperatures (b)
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identified as 2-keto-HFB1 and two cyclic hemiketals
formed by ring closure between the 2-keto moiety and
the 5-OH. While the hemiketals have already been
described (Blackwell et al. 1999), the open-chain keto
form has not yet been characterized.
Discussion
Gastrointestinal detoxification of fumonisins by specific
enzymes is a promising concept to ameliorate the effects
that fumonisins, which are frequently found as natural
contaminants of maize in large parts of the world, have on
the health and performance of domestic animals. It is
important to know the characteristics of an enzyme-
catalyzed reaction before a technological application can
be considered. We determined some key properties of the
aminotransferase FumI of Sphingopyxis sp. MTA144 with
respect to its reaction with fumonisins. The enzyme is
active with hydrolyzed FB1, the first intermediate in all
known pathways of FB1 catabolism, and not with FB1 itself
and catalyzes the transfer of the 2-amino group onto a
suitable acceptor (Heinl et al. 2010). Since the
corresponding amino group of structurally similar sphinga-
nine is acylated by ceramide synthase, which is the
molecular target that is inhibited by fumonisins (Wang et
al. 1991), the deamination reaction can be considered as
important for detoxification of fumonisins. To our knowl-
edge, no reports on the toxicity of 2-keto-HFB1 have been
published, and we have not studied its toxicity yet.
However, the amino group is thought to play a key role
for the toxicity of FB1 (Gelderblom et al. 1993; Lu et al.
1997; Norred et al. 2001; Fernandez-Surumay et al. 2004),
and obviously, 2-keto-HFB1 cannot be acylated in a similar
way as HFB1 (Humpf et al. 1998; Seiferlein et al. 2007).
Therefore, it seems reasonable to speculate that 2-keto-HFB1
may be non-toxic.
Numerous aminotransferases have been identified and
studied since the first description of this class of enzymes
(Needham 1930), and several are used in industrial
applications for the production of a range of natural and
non-natural amino acids and amines (Taylor et al. 1998;
Fig. 6 LC–MS chromatograms
of samples from a HFB1
transamination reaction.
Samples of 10 μM HFB1 in
Teorell–Stenhagen buffer
(pH 8.0) at 35°C were taken
before (a), 30 min (b), or
240 min (c) after addition of
purified aminotransferase
FumI-HIS to a final concentra-
tion of 67 ng/ml. HFB1 and
2-keto-HFB1 were separated on
a C8 reversed phase column in
a formate–acetonitrile gradient
and detected in SIM mode
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Hwang et al. 2005; Zhu and Hua 2009). However, this is
the first characterization of an aminotransferase that
catalyzes deamination of a fumonisin. Our work may lead
to the further expansion of the range of aminotransferase
applications to mycotoxin detoxification. Since FB1 is not a
substrate for FumI, a possible technological application of
the enzyme will require its combined use together with a
fumonisin carboxylesterase such as FumD, so that HFB1,
the substrate of FumI, is generated by hydrolytic cleavage
of the two tricarballylic acid side chains of FB1. In this
respect, the substrate specificity of FumI is quite remark-
able, since the direct vicinity of the 2-amino group is
identical in FB1 and HFB1 (Fig. 1). Since HFB2 and HFB3
are also deaminated by the enzyme, the 10-hydroxyl and
5-hydroxyl groups of HFB1, which are lacking in HFB2
and HFB3, respectively, are apparently not essential for
substrate recognition. The ability of FumI to use several
different α-keto acids as amino group acceptors is also
noteworthy. Even though pyruvate was the preferred
co-substrate when various α-keto acids were tested at the
identical molar concentrations in our study, it is tempting
to speculate that the relaxed co-substrate specificity of FumI
may have biological significance for its function in Sphingo-
pyxis sp. MTA144. Depending on the available α-keto acids,
FumI could thus produce alanine from pyruvate, aspartate
from oxaloacetate, or glycine from glyoxylate in vivo. The
affinity of FumI for its co-substrate (Fig. 3), which is much
lower than the affinity for HFB1 (Fig. 8) when judged by the
KM values, may also be important for the enzyme in vivo,
since the compatible α-keto acids are also intermediates in
energy metabolism. In this context, it is interesting to note
that the fum gene cluster of Sphingopyxis sp. MTA144
encodes three genes, the tricarballylate proton symport pump
FumG, the tricarballylate dehydrogenase FumE, and the
citrate utilization protein B FumF, which supposedly allow
utilization of the two tricarballylic acid side chains of FB1
and their conversion to citric acid (Heinl et al. 2010).
Oxaloacetate and glyoxylate, which both accept the
amino group during the FumI-catalyzed reaction, can
both be generated from citric acid in the Krebs cycle or
the glyoxylate cycle. For a technological application of
FumI, this co-substrate requirement together with the
comparatively low KM value implies that pyruvate or one
of the other suitable α-keto acids will have to be present or
will have to be provided together with the enzyme at
Fig. 7 Stability of FumI-HIS at various pH values (a) and temper-
atures (b). Fourteen micrograms per milliliter FumI-HIS was
incubated in Teorell–Stenhagen buffer at the indicated pH at 35°C
(a) or in the same buffer at pH 8.0 at the indicated temperature (b) for
1 h. Residual enzyme activity was determined as described in
Materials and Methods. The measured activities after incubation at
pH 8.0 (a) or without preincubation (b) were set to 100%
Fig. 8 Initial HFB1 deamination reaction rate as a function of
substrate concentration. The reactions were performed with 10 ng/ml
FumI-HIS and 5 mM pyruvate, a saturating co-substrate concentra-
tion, at 35°C in 20 mM Tris–HCl pH 8.0, 20 μM PLP, 0.1 mg/ml
BSA. HFB1 concentrations ranged from 0.1 to 100 μM
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millimolar concentration to enable efficient and fast HFB1
deamination. However, if the enzyme is to be used for
gastrointestinal HFB1 deamination, this co-substrate require-
ment might be covered to some extent by the presence of
α-keto acids in the chymus. It cannot be excluded that
other amino group acceptors that we have not yet
identified may enable higher reaction rates even at low
concentration.
Blackwell et al. have noted before that 2-keto-HFB1 can
undergo cyclization between the 5-hydroxyl group and C-2
of 2-keto-HFB1 to form two isomers of a hemiketal, and
that this reaction is favored by the presence of methanol in
the solvent (Blackwell et al. 1999). We made the same
observation and adapted our procedure for purification and
NMR characterization of 2-keto-HFB1 to work without
methanol. Nevertheless, the NMR characterization showed
that our preparation of 2-keto-HFB1 was not pure, and the
signals indicative of the hemiketals were still present. As
the C-1–C-5 part of 2-keto-HFB1 resembles a simplified
ketose structure, an equilibrium between the open-chain
and cyclized forms may be the explanation for this behavior
since in carbohydrate chemistry, such equilibria are ubiq-
uitous. This may also be one reason that the 2-keto-HFB1
peaks that eluted from a C8 HPLC column were broader
than the HFB1 peaks.
Overexpression of FumI in E. coli and the subsequent
purification procedure (Hartinger et al. 2010) result in
enzyme preparations that apparently are not saturated with
the prosthetic group PLP, as can be concluded from the
finding that addition of PLP to such an enzyme preparation
enhances activity. Aminotransferases were reported to
occur as mixtures of their apo- and holo-forms also when
isolated from their natural environment (Moss 1976).
Increasing the PLP concentrations above 10 μm in the
reconstitution experiments of recombinant FumI-HIS
showed no further increase of aminotransferase activity,
which is consistent with the tight binding of PLP that has
been reported for other aminotransferases (Ford et al. 1980;
Eliot and Kirsch 2004). If batches of enzyme need to be
prepared for technological application in the future, they
can be saturated with low concentrations of PLP before
their application to ensure that FumI is predominantly
available as a holoenzyme.
FumI-HIS displayed HFB1 deamination activity in all
buffers we tested, and these covered a wide range of salt
concentrations (Fig. 4). This indicates that the proposed
application of FumI is unlikely to be limited by buffer salt
requirements. The lack of enzyme activity at acidic pH
(Fig. 5a) rules out that FumI is already active in the
stomach when provided as an animal feed supplement.
2-Keto-HFB1 α-Hemiketal
a β-Hemiketala
1H 13C 1H 13C 1H 13C
1 2.14 25.8 1.32 22.8 1.29 25.0
2 – 212.4 – 106.9 – 102.2
3 4.28 75.7 3.87 78.2 3.80 76.8
4 1.72, 1.50 41.4 2.40, 1.35 40.5 2.23, 1.52 38.9
5 3.70 68.7 3.97 77.0 3.80 76.1
6 1.50–1.40 38.8 1.58, 1.44 37.4 1.45–1.40 38.5
7 1.45–1.25 ≈27 1.45–1.25 ≈27 1.45–1.25 ≈27
8 1.45–1.25 ≈27 1.45–1.25 ≈27 1.45–1.25 ≈27
9 1.40–1.35 39.4 1.40–1.35 39.4 1.40–1.35 39.4
10 3.59 69.8 3.59 69.8 3.59 69.8
11 1.48, 1.06 44.4 1.48, 1.06 44.4 1.48, 1.06 44.4
12 1.87 26.9 1.87 26.9 1.87 26.9
12-Me 0.94 21.7 0.94 21.7 0.94 21.7
13 1.40–1.25 40.1 1.40–1.25 40.1 1.40–1.25 40.1
14 3.61 70.2 3.61 70.2 3.61 70.2
15 3.16 80.2 3.16 80.2 3.16 80.2
16 1.55 35.6 1.55 35.6 1.55 35.6
16-Me 0.84 16.4 0.84 16.4 0.84 16.4
17 1.61, 1.20 32.2 1.61, 1.20 32.2 1.61, 1.20 32.2
18 1.36, 1.20 30.0 1.36, 1.20 30.0 1.36, 1.20 30.0
19 1.25–1.35 23.9 1.25–1.35 23.9 1.25–1.35 23.9
20 0.90 14.5 0.90 14.5 0.90 14.5
Table 1 1H and 13C NMR
assignment of 2-keto-HFB1 and
its hemiketal forms
aα/β according to Blackwell et al.
(1999)
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However, FumI can be expected to function in sections of
the upper intestine where the pH is close to neutral or even
slightly higher. The temperature optimum of 35°C and good
activity at 40°C found for FumI-HIS (Fig. 5b) imply that
the actual body temperature of animals, which e.g. was
reported to be 38.8°C for piglets (Ingram and Legge 1970),
should be well suited for high enzyme activity. Based on
our determination of pH stability (Fig. 7a), it will be
necessary to provide FumI in a formulation that enables
shuttling through the stomach without inactivation at low
pH. Simultaneously, the enzyme could thus be protected
from proteolytic degradation. Technologies for microen-
capsulation and targeted release in the intestine have
previously been developed (Champagne and Fustier 2007).
We were surprised to see a reduction of HFB1
deamination activity after preincubation of FumI-HIS at
7°C, because we had observed that a preparation of enzyme
that was stored in the fridge apparently retained full activity
over several weeks. Maybe handling of the enzyme at low
concentration contributed to the observed loss of activity.
Likewise, the maximal specific reaction rate measured in
the experiment shown in Fig. 8, using 10 ng/ml FumI-HIS,
was lower than in the experiment shown in Fig. 3, when
94 ng/ml FumI-HIS was used.
The KM value we determined for HFB1 deamination,
1.1 μM, corresponds to 0.794 mg/kg FB1. Since the
fumonisin concentrations frequently found in maize (Binder
et al. 2007; Gonzalez Pereyra et al. 2008; Gong et al. 2009;
Monbaliu et al. 2010) and known to have toxic effects on
animals (Ross et al. 1991; Taranu et al. 2005) are higher,
FumI should have sufficient affinity for the substrate HFB1
to enable detoxification in the range of fumonisin concen-
trations that are relevant in agriculture. The decrease of
FumI activity observed at HFB1 concentrations higher than
10 μM, which is equivalent to 7.22 mg/l FB1, can be
interpreted as substrate inhibition. Since the guidance
value for the maximum acceptable concentration of FB1
and FB2 in e.g. pig feed is 5 mg/kg according to the
European Commission Recommendation 2006/576/EC,
this observed inhibition of activity at higher HFB1
concentrations may not be relevant from a technological
point of view. In case enzymatic detoxification by a
combination of FumD and FumI of a highly contaminated
commodity is required, substrate inhibition of FumI may
be avoided by adapting FumD activity to that of FumI, so
that the HFB1 is continuously formed in sub-inhibitory
concentrations.
Feed enzymes may be useful for the degradation of
antinutritive substances that are naturally contained in
agricultural commodities, or to enhance the nutritional
value of feed. The use of phytase as a feed enzyme to
release phosphate from phytate that is naturally contained
in plant material is well established (Lei and Porres 2003;
Rao et al. 2009). Based on the enzyme characteristics
reported here, FumI may also be suitable for future
applications as a feed enzyme to enhance the salubriousness
of maize that is naturally contaminated with fumonisins, if
the specific properties and requirements of FumI are
considered in this application.
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